RxDoctor Payments Data

Jenny Hanna

Nurse Practitioner · Fort Smith, ARNPI 1194174086

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,942, more than ten times the $13 reported in 2021. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,518in general payments, 2019–2025

Across 369 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$717
  • Novartis$693
  • AbbVie$605
  • Merck$591
  • Lilly USA, LLC$467
  • Eisai Inc.$300
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,13494%
  • Education$3846%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,518 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$89,332
Medicare patients
419
Services billed
2,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib21$243,136
XareltoRivaroxaban51$45,057
EliquisApixaban21$17,872
Anastrozole239$3,712
Megestrol Acetate13$2,075
Letrozole51$1,003
Exemestane12$931
Ondansetron OdtOndansetron18$557
Ondansetron Hcl38$391
Promethazine Hcl37$329
Albuterol Sulfate HfaAlbuterol Sulfate13$282
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$282
Dexamethasone15$260
Acyclovir14$230
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$116$243,13621 claims
Johnson & JohnsonXarelto$207$45,05751 claims
PfizerEliquis$152$17,87221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →